This inventor holds 2 USPTO granted patents. Top assignee: Ajinomoto Co., Ltd.. Active years: 1989-1990.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1989-1990
Title: Osamu Hiwatashi: Innovator in Pharmaceutical Chemistry
Introduction
Osamu Hiwatashi is a notable inventor based in Kawasaki, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative work on azulene derivatives. With a total of 2 patents to his name, Hiwatashi's inventions have the potential to impact the treatment of various health conditions.
Latest Patents
His latest patents focus on azulene derivatives and pharmaceutical compositions containing them. These compounds are characterized by specific structural formulas where R¹ and R² represent alkyl groups of 1 to 3 carbon atoms. Additionally, R³ can be an alkyl group of 1 to 6 carbon atoms, an aryl group of 6 to 9 carbon atoms, or an aralkyl group of 7 to 10 carbon atoms. These azulene derivatives exhibit antihyperlipidemic activity, making them valuable in the pharmaceutical industry. Many of the compounds developed by Hiwatashi are also considered novel in their own right.
Career Highlights
Osamu Hiwatashi is associated with Ajinomoto Co., Ltd., a company known for its advancements in food and pharmaceutical products. His work at Ajinomoto has allowed him to explore innovative solutions in drug development and contribute to the company's research initiatives.
Collaborations
Throughout his career, Hiwatashi has collaborated with esteemed colleagues such as Kahei Takase and Katsumi Suzuki. These partnerships have fostered a collaborative environment that enhances the research and development of new pharmaceutical compounds.
Conclusion
Osamu Hiwatashi's contributions to pharmaceutical chemistry through his patents on azulene derivatives highlight his role as an innovator in the field. His work continues to pave the way for advancements in medical treatments and showcases the importance of collaboration in scientific research.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
